Combination Therapy for Preventing Angiogenesis
AssigneeThe General Hospital Corporation
InventorsDaniel C. Chung, Yusuke Mizukami
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a combination therapy for inhibiting angiogenesis in a subject having, or at risk of having, an angiogenic disease/disorder. The method comprises both administering to the mammal an inhibitor of HIF-I and administering a second compound or agent that inhibits angiogenesis such as an inhibitor of IL-8, VEGF, angiopoietins, EGF, FGF, TGF, G-CSF, or PDGF. Administration of an inhibitor of hypoxia inducible factor-1 (HIF-I) in combination with an inhibitor of interleukin 8 (IL-8) is particularly useful for treatment of colon cancer, lung cancer, pancreatic cancer, and breast cancer.
Claims23
A method of treating undesired angiogenesis in a tissue of a subject having, or at risk of having, an angiogenic disease or disorder by use of a combination therapy comprising i) administering to said subject an inhibitor of hypoxia inducible factor-1 (HIF-1) and ii) administering to said subject a second anti-angiogenic agent wherein the second anti-angiogenic agent is an inhibitor of an angiogenic agent selected from the group consisting of:
- vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), fibroblast growth factor (FGF), transforming growth factor (TGF), granulocyte colony stimulating factor (GCSF), angiopoietin 1, and interleukin 8 (IL-8).
The method of claim 4, wherein said cancer is colon cancer.
A method of treating undesired angiogenesis in a tissue of a subject having, or at risk of having, cancer by use of a combination therapy comprising i) administering to said subject an inhibitor of hypoxia inducible factor-1 (HIF-1) and ii) administering to said subject an inhibitor of interleukin 8 (IL-8), wherein said cancer is selected from the group consisting of colon cancer, pancreatic cancer, lung cancer, and breast cancer.
A method of treating undesired angiogenesis in a tissue of a subject having, or at risk of having, an angiogenic disease or disorder by use of a combination therapy comprising i) administering to said subject an inhibitor of hypoxia inducible factor-1 (HIF-1) and ii) administering to said subject a second anti-angiogenic agent wherein the second anti-angiogenic agent is a direct angiogenesis inhibitor selected from the group consisting of:
- endostatin, angiostatin, thrombospondin and tumstatin.
A kit designed for treatment of a subject having, or at risk of having, an angiogenic disease or disorder comprising an inhibitor of hypoxia inducible factor-1 (HIF-1) and at least one other anti-angiogenic agent, wherein the anti-angiogenic agent is selected from the group consisting of:
- an inhibitor of IL-8, an inhibitor of vascular endothelial growth factor (VEGF), an inhibitor of angiopoietin 1, an inhibitor of epidermal growth factor (EGF), an inhibitor of platelet derived growth factor (PDGF), an inhibitor of fibroblast growth factor (FGF), an inhibitor of transforming growth factor (TGF), and an inhibitor of granulocyte colony stimulating factor (G-CSF).
A kit designed for treatment of a subject having, or at risk of having, an angiogenic disease or disorder comprising an inhibitor of hypoxia inducible factor-1 (HIF-1) and at least one other anti-angiogenic agent, wherein the anti-angiogenic agent is selected from the group consisting of endostatin, angiostatin, thrombospondin, and tumstatin.
Dependencies are inferred from the claim text.